Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 13th January 2021
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer announces collaboration with PetMedix
PetMedix's Ky9 platform can rapidly and efficiently generate fully canine therapeutic antibodies.
Partnership will see the development of companion animal antibody therapeutics.

Boehringer Ingelheim has announced a multi-year partnership with PetMedix - a Cambridge-based biopharmaceutical firm - to develop novel and transformative companion animal antibody therapeutics.

The collaboration will see PetMedix undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market. The terms of the partnership have not been disclosed. 

PetMedix’s breakthrough approach to therapeutic antibodies has resulted in a number of successful, novel therapies for humans. It is also the only company in the world that has been able to bring this approach to veterinary medicine.

Through its its Ky9™ platform, PetMedix can rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.

Dr Tom Weaver, CEO of PetMedix, said: “We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals.”

James Allan, global head of transaction, business development & licensing, Boehringer Ingelheim Animal Health, added: “Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own”.

Become a member or log in to add this story to your CPD history

Applications open for MMI research grants

News Story 1
 RCVS' Mind Matters Initiative (MMI) has launched round two of its veterinary mental health research grants.

Researchers have until 11.59pm on Wednesday, 28 May 2025 to apply for a grant for research which reflects MMI's 2025 focus areas.

Only one Impact Grant was awarded last year, and so this year there are two Discovery Grants and one Impact Grants available. Each Discovery Grant is worth £5,000 and the Impact Grant is worth £15,000.

For more information or to apply, email researchgrants@rcvs.org.uk to contact the MMI team.

 

Click here for more...
News Shorts
BBC Radio 4 documentary addresses corporate fees

BBC Radio 4's File on 4 Investigates has released a documentary exploring how corporate-owned veterinary practices may be inflating bills to increase profit.

Released on 15 April, 'What's Happening To Your Vet Bills?' revealed the policies which many corporate groups have in place to increase their profits. This included targets and upgrades which veterinary teams are tasked with meeting on a regular basis.

It also features Anrich Vets, an independently-owned practice based in Wigan. Following the case of Staffordshire terrier Benjy, who is diagnosed with a tumour, the documentary shares how the team were able to offer contextualised care and advice to make the procedure as affordable as possible for his owners.

The documentary can be heard on demand on BBC iPlayer.